濮阳东方看妇科价格比较低濮阳东方口碑高,濮阳东方医院治疗早泄怎么收费,濮阳东方医院男科治疗阳痿可靠吗,濮阳东方医院男科治阳痿技术值得信任,濮阳东方看男科收费标准,濮阳东方男科好么,濮阳市东方医院看病好吗

Given the continued customer demand we expect over the coming months, we’ll be bringing on an additional 300,000 full-service shoppers to support cities nationwide. As more people look for immediate, flexible earnings opportunities during this time, we hope that Instacart can be an additional source of income for those looking to earn while also delivering for the communities in which they live. 406

Hold off on that funeral dirge for Macy's. The department store isn't dead yet.Macy's topped Wall Street's profit forecasts Tuesday and provided a healthy outlook for this year.The results strongly suggest there is still room for traditional stores in the mall in a world increasingly dominated by the likes of Amazon and Walmart.Macy's chairman and CEO Jeff Gennette said the company was "encouraged" by improvement at the company's brick-and-mortar stores and continued growth in online sales.Gennette said digital revenue posted a double-digit percentage increase for the 34th quarter in a row, a run of more than eight years.And the company is still investing heavily in its Bluemercury chain of specialty beauty stores and the discount outlet Backstage. Macy's said it opened 36 Bluemercury stores and 30 Backstage stores last year, even as it closed 16 Macy's stores.Gennette added during a conference call with analysts that Macy's plans to open 100 more Backstage locations this year, including in malls.Macy's is also selling real estate to shore up its balance sheet. The company said it raised 1 million last year and .3 billion over the past three years by getting rid of some stores, warehouses and parking garages.Macy's is also working with real estate company Brookfield Asset Management on other transactions.Macy's said Tuesday it is selling several floors in its State Street store in Chicago to a real estate fund backed by Brookfield for million. Brookfield plans to convert the floors into office space.All this is good news for Macy's. But one analyst said Macy's needs to do more before its turnaround qualifies as a true Miracle on 34th Street."There is a long tail of shops that look dated, are in sub-optimal locations, and where the customer experience is poor. Macy's must remedy this if it is to transform the business," Neil Saunders, managing director of GlobalData Retail, said in a report.Nonetheless, the real estate transactions and improved sales outlook are two reasons Wall Street has fallen in love with Macy's again.The stock surged nearly 12% in early trading before pulling back a bit. Macy's has soared more than 45% in the past six months.Department store chains Kohl's, Nordstrom and JCPenney — which will all report results later this week — rallied as well Tuesday. Another chain, Dillard's, rose 12% too after it also posted strong quarterly results.Investors are clearly betting that Macy's wasn't the only traditional retailer that had a happy holiday season. 2527

GRAND RAPIDS, Mich. — As we get closer to a potential COVID-19 vaccine approval in the U.S., doctors are hoping the public actually gets the vaccine once it’s available.Recent polling from Pew Research shows about 60% of Americans say they would ‘definitely’ or ‘probably’ get a COVID-19 vaccine.Local infectious disease doctors tell WXMI that that number will be just enough to put a serious dent in infections, but the more immunity, the better.Dr. Andrew Jameson, the Division Chief for Infectious Disease at Mercy Health said, “I am optimistic for the first time in a while.”Dr. Jameson added that he’s seeing a bit of light at the end of a very long tunnel with a COVID vaccine approval potentially just days away.“I can tell you right now from what I’ve seen, from an efficacy standpoint, from a safety standpoint, I am going to be definitely getting the vaccine personally and I have zero issues of giving my family the vaccine when it’s available,” Dr. Jameson said.With two COVID-19 vaccines on deck for approval with the FDA, one from Pfizer and one from Moderna, Dr. Jameson is hoping that people feel confident in getting it once they’re able.“If we get about 60% of people immunized and then we also have the natural immunity out there giving us a little bit of extra help, I think that is going to be a huge impact,” Dr. Jameson said.Dr. Jameson said he also understands that people may be wary of such a new vaccine.“Unfortunately, we’ve had a fair amount of skepticism in the community about vaccines before all of this, and now in the setting of this being moved forward pretty quickly, I think there’s probably a little bit of a natural skepticism,” he said.He said the biggest reason he’s heard for not wanting the vaccine is that things are just moving too fast.“Before this, the fastest that we ever had a vaccine get from the beginning to the end to where people were getting it, was four years, and this one is going to be about 10 months,” Dr. Jameson said.Dr. Jameson called the trial and manufacturing process of both companies vaccines, ‘the most transparent’ he’s ever seen and trusts the FDA to leave no stone unturned before approval.“They get all the notes from the doctors, they get all the patient encounter visits from the sites that are doing the vaccine, so they actually get all of the raw data and re-interpret it and re-analyze it themselves for efficacy, so they don’t just believe what the drug manufacturers tell them,” he explained.He wants people to also understand potential vaccine side effects, to make sure they come back for their second dose. Both Moderna and Pfizer vaccines require two doses given several weeks apart to reach full effectiveness.“If I know that my arm is going to hurt, and I might have a headache, and I might feel run-down for a day or two, if I know that, it’s very different than if that’s a surprise to me,” he said.The FDA is scheduled to meet on Thursday to review the Pfizer vaccine and then again on Dec. 17 to look over Moderna’s vaccine.This story was first reported by Annie Szatkowski at WXMI in Grand Rapids, Michigan. 3109

HAMPTON ROADS, Va. - A Virginia company is unveiling a brand new technology, with help from jellyfish, to help in the fight against COVID-19.“We're just pretty motivated by the fact that we're making an impact to open the economy, places back up safely,” Senseware CEO Dr. Serene Al-Momen told News 3.Senseware, a technology company based in northern Virginia, specializes in air monitoring.“We quickly realized that the primary concerns of transmissions are airborne transmission for the COVID-19 virus,” Al-Momen said.The technology the company is rolling out is a new pathogen-detecting monitoring system using specific antibodies and proteins from jellyfish that light up when coming in contact with COVID-19.“We're talking about having the results available within minutes, under five minutes,” she said. “If the virus is detected, we immediately in real-time with our cloud-based technology alert you. You see the threat, the detection on your phone. You get an email if you're an operator. You're able to quickly mitigate that issue.”Al-Momen told News 3 the product is in the final stages of third-party testing. She added they’re also looking throughout Virginia, including Hampton Roads, for beta testing sites, specifically healthcare and treatment centers.“This is creating a way to create a safer environment and begin to create that confidence in people to re-populate spaces,” she said.She said it's all about keeping people safe and giving them peace of mind.“Knowledge is power,” Al-Momen said. “When you're having that real-time, around the clock, monitoring of all aspects of air quality, it will create that confidence for people to know that there's that data available in real-time.”This story was first reported by Zak Dahlheimer at WTKR in Norfolk, Virginia. 1790

Hackers breached an Equifax payroll-related service in March, months before the company said criminals accessed the personal records of 143 million people.On Monday, Equifax said the March incident was unrelated to the recently disclosed hack that occurred between May and July 2017."The criminal hacking that was discovered on July 29 did not affect the customer databases hosted by the Equifax business unit that was the subject of the March event," Equifax said in a statement.Security breach disclosure laws require businesses to disclose hacks if they include personal identifiable information like social security numbers, drivers licenses or state IDs. Equifax says it reported the March incident to customers, affected individuals and regulators.According to a report from Bloomberg, an insider says the same intruders were involved in both breaches. However, Equifax denies the incidents are related.Equifax did not provide additional information about the March breach, but journalist Brian Krebs reported that between April 2016 and March 2017, hackers accessed tax records through Equifax subsidiary TALX, a payroll and tax service provider.Equifax hired cybersecurity firm Mandiant to investigate both the March and July incidents."Mandiant has investigated both events and found no evidence that these two separate events or the attackers were related," Equifax said in a statement.The vulnerability used to access 143 million records was disclosed in March. Equifax has said it was aware of the vulnerability at the time and took efforts to patch it, however, the hackers used the flaw to steal information months later. The credit reporting agency announced the breach on Sept. 8 and confirmed the breach occurred between mid-May and July.It is unknown who was responsible for the hack disclosed earlier this month.The FBI and the Federal Trade Commission are investigating the breach. Two Equifax executives -- its chief information officer and chief security officer -- retired on Friday. 2089